List of works - Qianbin Li

3,5-Disubstituted-thiazolidine-2,4-dione analogs as anticancer agents: design, synthesis and biological characterization.

scientific article

Binding pocket-based design, synthesis and biological evaluation of novel selective BRD4-BD1 inhibitors

scientific article published on 22 March 2019

Design, synthesis and anti-fibrosis activity study of N₁-substituted phenylhydroquinolinone derivatives.

scientific article published on 2 February 2012

Discovery of 1-(4-((3-(4-methylpiperazin-1-yl)propyl)amino)benzyl)-5-(trifluoromethyl)pyridin-2(1H)-one, an orally active multi-target agent for the treatment of diabetic nephropathy

scientific article published on 4 July 2017

Discovery of 3-(2-aminoethyl)-5-(3-phenyl-propylidene)-thiazolidine-2,4-dione as a dual inhibitor of the Raf/MEK/ERK and the PI3K/Akt signaling pathways.

scientific article published on 8 June 2010

Dual inhibitors of RAF-MEK-ERK and PI3K-PDK1-AKT pathways: Design, synthesis and preliminary anticancer activity studies of 3-substituted-5-(phenylamino) indolone derivatives

scientific article published on 26 January 2019

Inhibitors of 11β-Hydroxylase (CYP11B1) for Treating Diseases Related to Excess Cortisol.

scientific article

Novel 3-galloylamido-N'-substituted-2,6-piperidinedione-N-acetamide peptidomimetics as metalloproteinase inhibitors

scientific article published on 05 January 2007

Novel anticancer targets and drug discovery in post genomic age.

scientific article

Novel cyclic-imide peptidomimetics as aminopeptidase N inhibitors. Design, chemistry and activity evaluation. Part I.

scientific article published on 30 July 2009

Novel cyclic-imide peptidomimetics as aminopeptidase N inhibitors. Structure-based design, chemistry and activity evaluation. II

scientific article published on 14 January 2010

Novel potent 2,5-pyrrolidinedione peptidomimetics as aminopeptidase N inhibitors. Design, synthesis and activity evaluation.

scientific article

Soluble Guanylate Cyclase: a New Therapeutic Target for Fibrotic Diseases

scientific article published on 8 May 2017

Structure-activity relationship (SAR) studies of 3-(2-amino-ethyl)-5-(4-ethoxy-benzylidene)-thiazolidine-2,4-dione: development of potential substrate-specific ERK1/2 inhibitors.

scientific article published on 18 September 2009

The RAF-MEK-ERK pathway: targeting ERK to overcome obstacles to effective cancer therapy.

scientific article published on January 2015

Therapeutic strategies of diabetic nephropathy: recent progress and future perspectives

scientific article

List of works by Qianbin Li

3,5-Disubstituted-thiazolidine-2,4-dione analogs as anticancer agents: design, synthesis and biological characterization.

Binding pocket-based design, synthesis and biological evaluation of novel selective BRD4-BD1 inhibitors

Design, synthesis and anti-fibrosis activity study of N₁-substituted phenylhydroquinolinone derivatives.

Discovery of 1-(4-((3-(4-methylpiperazin-1-yl)propyl)amino)benzyl)-5-(trifluoromethyl)pyridin-2(1H)-one, an orally active multi-target agent for the treatment of diabetic nephropathy

Discovery of 3-(2-aminoethyl)-5-(3-phenyl-propylidene)-thiazolidine-2,4-dione as a dual inhibitor of the Raf/MEK/ERK and the PI3K/Akt signaling pathways.

Dual inhibitors of RAF-MEK-ERK and PI3K-PDK1-AKT pathways: Design, synthesis and preliminary anticancer activity studies of 3-substituted-5-(phenylamino) indolone derivatives

Inhibitors of 11β-Hydroxylase (CYP11B1) for Treating Diseases Related to Excess Cortisol.

Novel 3-galloylamido-N'-substituted-2,6-piperidinedione-N-acetamide peptidomimetics as metalloproteinase inhibitors

Novel anticancer targets and drug discovery in post genomic age.

Novel cyclic-imide peptidomimetics as aminopeptidase N inhibitors. Design, chemistry and activity evaluation. Part I.

Novel cyclic-imide peptidomimetics as aminopeptidase N inhibitors. Structure-based design, chemistry and activity evaluation. II

Novel potent 2,5-pyrrolidinedione peptidomimetics as aminopeptidase N inhibitors. Design, synthesis and activity evaluation.

Soluble Guanylate Cyclase: a New Therapeutic Target for Fibrotic Diseases

Structure-activity relationship (SAR) studies of 3-(2-amino-ethyl)-5-(4-ethoxy-benzylidene)-thiazolidine-2,4-dione: development of potential substrate-specific ERK1/2 inhibitors.

The RAF-MEK-ERK pathway: targeting ERK to overcome obstacles to effective cancer therapy.

Therapeutic strategies of diabetic nephropathy: recent progress and future perspectives